ArticleHaematologica2011
LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.
Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies.Experimental hematology & oncology · 2025Review
- Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy.Annals of hematology · 2024Article
- Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment.Clinical and experimental medicine · 2024Review
- The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review.Advances in hematology · 2024Review
- Article
- Lipotoxicity as a Barrier for T Cell-Based Therapies.Biomolecules · 2022Review
- Review
- Characterization of lipid droplet metabolism patterns identified prognosis and tumor microenvironment infiltration in gastric cancer.Frontiers in oncology · 2022Article
- Heterozygous lipoprotein lipase knockout mice exhibit impaired hematopoietic stem/progenitor cell compartment.Animal models and experimental medicine · 2021Article
- Chromatin interaction neural network (ChINN): a machine learning-based method for predicting chromatin interactions from DNA sequences.Genome biology · 2021Article
- Multi-Omics Analysis of Fatty Acid Metabolism in Thyroid Carcinoma.Frontiers in oncology · 2021Article
- MicroRNA-425 inhibits proliferation of chronic lymphocytic leukaemia cells through regulation of the Bruton's tyrosine kinase/phospholipase Cγ2 signalling pathway.Experimental and therapeutic medicine · 2020Article
- Lipid metabolism and lipophagy in cancer.Biochemical and biophysical research communications · 2018Review
- The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.Hematology. American Society of Hematology. Education Program · 2017Review
- Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression.Molecules (Basel, Switzerland) · 2017Review
- Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia.Pathology oncology research : POR · 2017Article
- Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.Oncogene · 2016Article
- UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?Haematologica · 2016Article
- Proteins interaction network and modeling of IGVH mutational status in chronic lymphocytic leukemia.Theoretical biology & medical modelling · 2015Article
- Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.Molecular cancer research : MCR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia. However, few studies have systematically compared these different RNA-based markers. DESIGN AND
methodsUsing real-time quantitative PCR, we measured the mRNA expression levels of these genes in unsorted samples from 252 newly diagnosed chronic lymphocytic leukemia patients and correlated our data with established prognostic markers (for example Binet stage, CD38, IGHV gene mutational status and genomic aberrations) and clinical outcome.
resultsHigh expression levels of all RNA-based markers, except MCL1, predicted shorter overall survival and time to treatment, with LPL being the most significant. In multivariate analysis including the RNA-based markers, LPL expression was the only independent prognostic marker for overall survival and time to treatment. When studying LPL expression and the established markers, LPL expression retained its independent prognostic strength for overall survival. All of the RNA-based markers, albeit with varying ability, added prognostic information to established markers, with LPL expression giving the most significant results. Notably, high LPL expression predicted a worse outcome in good-prognosis subgroups, such as patients with mutated IGHV genes, Binet stage A, CD38 negativity or favorable cytogenetics. In particular, the combination of LPL expression and CD38 could further stratify Binet stage A patients.
conclusionsLPL expression is the strongest RNA-based prognostic marker in chronic lymphocytic leukemia that could potentially be applied to predict outcome in the clinical setting, particularly in the large group of patients with favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.